Results 11 to 20 of about 21,815 (286)
Osteoarthritis background therapy: current view on the glucosamine and chondroitin therapy
The article highlights the current status of symptomatic slow-acting drugs (SYSADOA) in osteoarthritis (OA). Mechanism of action, clinical studies data on the effectiveness of glucosamine (GA) and chondroitin sulfate (CS) and their combinations in OA ...
L. I. Alekseeva, A. M. Lila
doaj +1 more source
Chondroitin for osteoarthritis [PDF]
Osteoarthritis, a common joint disorder, is one of the leading causes of disability. Chondroitin has emerged as a new treatment. Previous meta-analyses have shown contradictory results on the efficacy of chondroitin. This, in addition to the publication of more trials, necessitates a systematic review.To evaluate the benefit and harm of oral ...
Jasvinder A, Singh +3 more
openaire +2 more sources
The combined use of drugs with different mechanisms of action is the main principle of musculoskeletal pain control in rheumatic diseases. However, there are few studies evaluating the efficacy of this approach in real practice.Objective: to determine ...
A. E. Karateev +37 more
doaj +1 more source
Molecular Cloning of a Chondroitin Polymerizing Factor That Cooperates with Chondroitin Synthase for Chondroitin Polymerization [PDF]
We recently cloned human chondroitin synthase (ChSy) exhibiting the glucuronyltransferase-II (GlcATII) and N-acetylgalactosaminyltransferase-II (GalNAcTII) activities responsible for the biosynthesis of repeating disaccharide units of chondroitin sulfate, but chondroitin polymerization was not demonstrated in vitro using the recombinant ChSy. We report
Hiroshi, Kitagawa +3 more
openaire +2 more sources
During liver fibrogenesis, there is an imbalance between regeneration and wound healing. The current treatment is the withdrawal of the causing agent; thus, investigation of new and effective treatments is important.
Pedro L. R. Guedes +8 more
doaj +1 more source
Introduction Musculoskeletal conditions are often characterized by pain, as well as limited physical function. To alleviate pain accompanying musculoskeletal diseases, non-steroidal anti-inflammatory drugs (NSAIDs) and/or paracetamol are used.
Paulina Pluta +2 more
doaj +1 more source
Identification of Chondroitin Sulfate Glucuronyltransferase as Chondroitin Synthase-3 Involved in Chondroitin Polymerization [PDF]
Recently, we demonstrated that chondroitin polymerization is achieved by any two combinations of human chondroitin synthase-1 (ChSy-1), ChSy-2 (chondroitin sulfate synthase 3, CSS3), and chondroitin-polymerizing factor (ChPF). Although an additional ChSy family member, called chondroitin sulfate glucuronyltransferase (CSGlcA-T), has been identified ...
Tomomi Izumikawa +5 more
openaire +2 more sources
Chondroitin synthase KfoC is a bifunctional enzyme which polymerizes the capsular chondroitin backbone of Escherichia coli K4, composed of repeated β3N-acetylgalactosamine (GalNAc)-β4-glucuronic acid (GlcA) units. Sugar donors UDP-GalNAc and UDP-GlcA are
Mélanie Leroux +5 more
doaj +1 more source
Osteoarthritis is a very disabling disease that can be treated with both non-pharmacological and pharmacological approaches. In the last years, pharmaceutical-grade chondroitin sulfate (CS) and glucosamine emerged as symptomatic slow-acting molecules ...
Donatella Cimini +11 more
doaj +1 more source
Symptomatic delayed-acting drugs (SYSADOA): new applications
The review systematizes modern data indicating effective pain control and a significant improvement in the functional activity of patients suffering from osteoarthritis (OA) using pharmaceutical substances of chondroitin sulfate (CS) and glucosamine (GA).
A. M. Lila +3 more
doaj +1 more source

